Drugs / RTX001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06823713 | Oct 2024 → Aug 2028 expected | chronic liver failure, cirrhosis of liver, fatty liver disease | Resolution Therapeutics Limited | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 6
| Date | Issuer | Release |
|---|---|---|
| 2026-05-12 | Resolution Therapeutics Limited | Results Resolution Therapeutics to showcase key preclinical data on its Regenerative Macrophage Therapy (RMT) RTX001 in oral presentation at ASGCT 2026 resolution-tx.com ↗
These new preclinical data demonstrate RTX001’s pharmacology, safety, tolerability, and efficacy in mouse models, with reduced fibrosis and inflammation observed |
| 2025-11-07 | Resolution Therapeutics Limited | Results Resolution Therapeutics announces new data showcasing the potential of Regenerative Macrophage Therapy in treating cirrhosis at AASLD 2025 resolution-tx.com ↗
New preclinical data from Resolution’s first engineered Regenerative Macrophage Therapy, RTX001, shows significant reduction of systemic inflammation |
| 2025-05-14 | Resolution Therapeutics Limited | Results Resolution Therapeutics Announces Regenerative Macrophage Therapy (RMT) Manufacturing Process & Candidate Testing Suite at ASGCT 2025 resolution-tx.com ↗
Novel mode of action-based candidate testing suite enabled the discovery of RTX001, which shows enhanced anti-inflammatory and anti-fibrotic effects in vitro and in vivo. |
| 2024-11-19 | Resolution Therapeutics Limited | Regulatory Resolution Therapeutics Announces Approval of Clinical Trial Application by AEMPS to Expand Phase 1/2 EMERALD Study of RTX001 into Spain resolution-tx.com ↗
Resolution Therapeutics Limited (“Resolution”), a clinical-stage biopharmaceutical company pioneering regenerative macrophage therapies in inflammatory and fibrotic diseases, today announces it has received approval of a clinical trial application from the Spanish Agency of Medicines and Medical Products (AEMPS) to commence the Phase 1/2 EMERALD Study evaluating its lead candidate RTX001 in Spain. |
| 2024-11-11 | Resolution Therapeutics Limited | Results Resolution Therapeutics Announces New Clinical and Preclinical Data Showcasing Regenerative Macrophage Therapy at AASLD 2024 resolution-tx.com ↗
New preclinical data support superior anti-inflammatory and anti-fibrotic effect of RTX001, an engineered macrophage investigational therapy, compared to non-engineered macrophages. |
| 2024-06-27 | Resolution Therapeutics Limited | Regulatory Resolution Therapeutics Receives MHRA Approval to Commence Phase I/II EMERALD Study for Lead Candidate RTX001 resolution-tx.com ↗
Resolution Therapeutics Limited (“Resolution”), a clinical-stage biopharmaceutical company developing macrophage cell therapies to treat end-stage liver disease today announces it has received approval from the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) to commence a Phase I/II EMERALD study for its lead candidate RTX001. |
All press releases naming this drug 8 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RTX001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06823713 ↗ |
| Modality | Cell therapy | “RTX001 is an autologous engineered regenerative macrophage cell therapy” NCT06823713 ↗ |
| Route | Intravenous | “receive a maximum of four doses of RTX001 by intravenous infusion” NCT06823713 ↗ |